{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:58:43Z","timestamp":1781215123165,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:00:00Z","timestamp":1792886400000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["ZIC SC 006537"],"award-info":[{"award-number":["ZIC SC 006537"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jchromb.2025.124833","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:32:02Z","timestamp":1761121922000},"page":"124833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Determination of the pyrrolo[2,3-d] pyrimidine antifolate AGF94 from a preclinical murine study using a simple UHPLC-MS\/MS assay"],"prefix":"10.1016","volume":"1267","author":[{"given":"Tryston T.","family":"Metz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C.","family":"Ashe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis C.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan C.","family":"Wilner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristbjorn O.","family":"Gudmundsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleem","family":"Gangjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry H.","family":"Matherly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serguei V.","family":"Kozlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2025.124833_bb0005","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399409000969","article-title":"Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues","volume":"11","author":"Zhao","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.jchromb.2025.124833_bb0010","article-title":"Folate transporter dynamics and therapy with classic and tumor-targeted antifolates","volume":"11","author":"O'Connor","year":"2021","journal-title":"Sci Rep-Uk."},{"key":"10.1016\/j.jchromb.2025.124833_bb0015","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/annonc\/mds212","article-title":"Dietary folates and cancer risk in a network of case-control studies","volume":"23","author":"Tavani","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jchromb.2025.124833_bb0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.critrevonc.2016.08.001","article-title":"Folates as adjuvants to anticancer agents: chemical rationale and mechanism of action","volume":"106","author":"Danenberg","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jchromb.2025.124833_bb0025","series-title":"Folate Receptors and Therapeutic Applications, Targeted Drug Strategies for Cancer and Inflammation","first-page":"35","author":"Kamen","year":"2011"},{"key":"10.1016\/j.jchromb.2025.124833_bb0030","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/dmd.113.055723","article-title":"The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in Antifolate chemotherapy of cancer","volume":"42","author":"Matherly","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2025.124833_bb0035","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-4791","article-title":"Impact of folate transport redundancies on the therapy with tumor-targeted and untargeted antifolates","volume":"79","author":"Hou","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.jchromb.2025.124833_bb0040","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4161\/cbt.22020","article-title":"The human proton-coupled folate transporter biology and therapeutic applications to cancer","volume":"13","author":"Desmoulin","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jchromb.2025.124833_bb0045","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.18632\/oncotarget.23321","article-title":"Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies","volume":"9","author":"Shen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jchromb.2025.124833_bb0050","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1021\/jm200739e","volume":"54","author":"Wang","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchromb.2025.124833_bb0055","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1021\/acs.biochem.6b00412","article-title":"Structural and enzymatic analysis of tumor-targeted Antifolates that inhibit Glycinamide ribonucleotide Formyltransferase","volume":"55","author":"Deis","year":"2016","journal-title":"Biochemistry-Us."},{"key":"10.1016\/j.jchromb.2025.124833_bb0060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.hoc.2012.02.002","article-title":"The Antifolates","volume":"26","author":"Visentin","year":"2012","journal-title":"Hematol Oncol Clin N."},{"key":"10.1016\/j.jchromb.2025.124833_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123514","article-title":"Methotrexate-induced neurotoxicity in oncology: current issues for a classic drug","volume":"473","author":"Besora","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jchromb.2025.124833_bb0070","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/jps.21515","article-title":"Molecular and Functional Characteristics of Proton-Coupled Folate Transporter","volume":"98","author":"Yuasa","year":"2009","journal-title":"J Pharm Sci-Us"},{"key":"10.1016\/j.jchromb.2025.124833_bb0075","article-title":"Targeted therapy of pyrrolo[2,3-]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment","volume":"12","author":"Wallace-Povirk","year":"2022","journal-title":"Sci Rep-Uk."},{"key":"10.1016\/j.jchromb.2025.124833_bb0080","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jms.4337","article-title":"Comparison of ESI-MS\/MS and APCI-MS methods for the quantification of folic acid analogs in","volume":"54","author":"Annibal","year":"2019","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2025.124833_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115034","article-title":"Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels","volume":"221","author":"Fleury-Souverain","year":"2022","journal-title":"J Pharmaceut Biomed."},{"key":"10.1016\/j.jchromb.2025.124833_bb0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpha.2019.06.001","article-title":"Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples","volume":"9","author":"Karami","year":"2019","journal-title":"J Pharm Anal."},{"key":"10.1016\/j.jchromb.2025.124833_bb0095","article-title":"Highly sensitive quantification of pemetrexed in human plasma using UPLC-MS\/MS to support microdosing studies","volume":"36","author":"Kolmer","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2025.124833_bb0100","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1021\/acsfoodscitech.5c00095","article-title":"Derivatization-based liquid chromatography-tandem mass spectrometry method for quantification of folate species: a cost-effective method for the health food industry","volume":"5","author":"Wang","year":"2025","journal-title":"Acs Food Sci Technol."},{"key":"10.1016\/j.jchromb.2025.124833_bb0105","series-title":"Bioanalytical Method Validation: Guidance for Industry","author":"U.F.A.D. Administration","year":"2018"},{"key":"10.1016\/j.jchromb.2025.124833_bb0110","series-title":"M10 Bioanalytical Method Validation And Study Sample Analysis: Guidance for Industry","author":"Administration","year":"2022"},{"key":"10.1016\/j.jchromb.2025.124833_bb0115","first-page":"1","article-title":"Enhancement and suppression of ionization in drug analysis using HPLC-MS\/MS in support of therapeutic drug monitoring: a review of current knowledge of its minimization and assessment","volume":"40","author":"George","year":"2018","journal-title":"Ther. Drug Monit."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225003873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225003873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:07:54Z","timestamp":1781212074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225003873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"alternative-id":["S1570023225003873"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124833","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of the pyrrolo[2,3-d] pyrimidine antifolate AGF94 from a preclinical murine study using a simple UHPLC-MS\/MS assay","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124833"}}